Amgen — Apr 30, 2026 release

Reconciliations of Cash Flows (In millions) (Unaudited) Three months ended March 31, 2026 2025 Net cash provided by operating activities $ 2,189  $ 1,391  Net cash used in investing activities (716) (447) Net cash provided by (used in) financing activities 1,436  (4,107) Increase (decrease) in cash and cash equivalents 2,909  (3,163) Cash and cash equivalents at beginning of period 9,129  11,973  Cash and cash equivalents at end of period $ 12,038  $ 8,810  Three months ended March 31, 2026 2025 Net cash provided by operating activities $ 2,189  $ 1,391  Capital expenditures (712) (411) Free cash flow $ 1,477  $ 980  AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS Page 23 Amgen Inc. Reconciliation of GAAP EPS Guidance to Non-GAAP EPS Guidance for the Year Ending December 31, 2026 (Unaudited) GAAP diluted EPS guidance $ 15.62  — $ 17.10  Known adjustments to arrive at non-GAAP*: Acquisition-related expenses (a) 6.02  — 6.10  Net losses from equity investments 0.15 Other (0.17) Non-GAAP diluted EPS guidance $ 21.70  — $ 23.10  * The known adjustments are presented net of their related tax impact, which amount to approximately $1.09 per share. (a) The adjustment primarily includes noncash amortization of intangible assets and fair value step-up of inventory acquired in business combinations. Our GAAP diluted EPS guidance does not include the effect of GAAP adjustments triggered by events that may occur subsequent to this press release such as acquisitions, asset impairments, litigation, changes in fair value of our contingent consideration obligations and changes in fair value of our equity investments. Reconciliation of GAAP Tax Rate Guidance to Non-GAAP Tax Rate Guidance for the Year Ending December 31, 2026 (Unaudited) GAAP tax rate guidance 14.5  % — 16.0  % Tax rate of known adjustments discussed above 0.5 % Non-GAAP tax rate guidance 15.0  % — 16.5  %